secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000899923-25-000084
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q2 revenue $213.1M (+1% YoY); raises FY2025 revenue guidance
----------------------------------------------------------------------------

- GAAP net loss $330.5M ($3.57/share) includes $316.7M impairment; adjusted EPS $0.05.
- Hereditary cancer testing revenue +9% YoY in Oncology; MyRisk with RiskScore volume +14%.
- Raised 2025 revenue guidance to $818-828M from $807-823M; adjusted EPS reiterated at $(0.02)-$0.02.
- New $200M credit facility with OrbiMed entered July 31; plans to launch ultra-sensitive MRD test H1 2026.
- GeneSight revenue down 12% due to UHC coverage discontinuation; prenatal revenue +7%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992325000084/0000899923-25-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992325000084/mygn-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000899923-25-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer